Quantum Genesis AI Corp. (OTC: QGAI) issued a statement on May 19, 2026, to clarify the relationship between the company and certain scientific research publications previously referenced in its press releases. The company emphasized that Quantumzyme LLP, a separate entity based in Bengaluru, India, is not a subsidiary or affiliate of Quantum Genesis AI. This clarification aims to distinguish the two entities and provide additional context regarding intellectual property rights transferred to the company.
The company noted that prior press releases from November 5, 2025, and February 12, 2026, referenced scientific publications related to its broader enzyme engineering and biocatalysis field. Those publications identified Quantumzyme LLP and reflected the affiliations of contributing researchers at the time the research was conducted. Quantum Genesis AI clarified that scientific publications arising from research activities undertaken by its Chief Executive Officer, Naveen Kulkarni, appropriately reflect the affiliations of the contributing researchers at the time the research was conducted and submitted.
According to the company, an Asset Purchase Agreement dated February 21, 2023, transferred certain intellectual property, know-how, methodologies, processes, research and development materials, and related rights associated with the company's core enzyme engineering and biocatalysis business from Mr. Kulkarni to Quantum Genesis AI. A subsequent confirmatory assignment was filed in the company's Current Report on Form 8-K on April 29, 2026, relating to certain intellectual property and technology associated with its enzyme engineering and biocatalysis platform.
Quantum Genesis AI believes that the Asset Purchase Agreement transferred underlying technology, methodologies, computational approaches, know-how, and related intellectual property. To the extent research activities conducted by Mr. Kulkarni, whether directly or through Quantumzyme LLP, relate to the company's core enzyme engineering and biocatalysis field and are based on or derived from the transferred technology platform, the company believes such intellectual property and technology fall within the scope of the rights transferred to the company. The company's prior disclosures relating to scientific publications were made on the basis of its ownership of the relevant intellectual property and technology associated with its business.
This clarification is significant for investors and stakeholders as it delineates the boundaries of Quantum Genesis AI's intellectual property assets and its relationship with Quantumzyme LLP. It addresses potential confusion arising from the overlapping research activities and underscores the company's ownership of key technologies in enzyme engineering and biocatalysis. For more information, visit qgaicorp.com and the company's profile at otcmarkets.com/stock/QGAI.
